ReviewDrug safety2016
Neuropsychiatric Effects of HIV Antiviral Medications.
Review in Drug safety, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 61 citations in OpenAlex.
- Clinical and behavioral predictors of HIV-associated neurocognitive disorder among people with HIV who use substances: a secondary analysis of the HOPE trial.Journal of neurovirology · 2026Trial
- Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.Journal of medical ethics · 2018Trial
- Effectiveness and safety of ainuovirine plus lamivudine and tenofovir DF in virologically suppressed people living with HIV-1: the 48-week results of a multicenter, real-world study.Antimicrobial agents and chemotherapy · 2026Observational
- Psychiatric comorbidities in HIV/AIDS patients and its overlap with neurological disorders.Discover mental health · 2025Review
- Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial.Infectious diseases and therapy · 2025Article
- Brain function abnormalities and neuroinflammation in people living with HIV-associated anxiety disorders.Frontiers in psychiatry · 2024Article
- Brain function abnormalities and inflammation in HIV-positive men who have sex with men with depressive disorders.Frontiers in psychiatry · 2024Article
- Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management.Nature reviews. Neurology · 2023Review
- Observational
- Article
- Delirium among people aging with and without HIV: Role of alcohol and Neurocognitively active medications.Journal of the American Geriatrics Society · 2023Article
- Assessment and Diagnosis of HIV-Associated Dementia.Viruses · 2023Review
- Influence of HIV infection on cognition and overall intelligence in HIV-infected individuals: advances and perspectives.Frontiers in behavioral neuroscience · 2023Review
- Midlife body mass index, central adiposity and neuropsychological performance over 10 years in women living with and without HIV.Frontiers in endocrinology · 2023Article
- Central nervous system and neuropsychiatric disturbances in people living with HIV.Le infezioni in medicina · 2023Review
- Neuroinflammation in HIV-associated depression: evidence and future perspectives.Molecular psychiatry · 2022Review
- Observational cohort study of rilpivirine (RPV) utilization in Europe.AIDS research and therapy · 2022Observational
- HIV Symptom Clusters are Similar Using the Dimensions of Symptom Occurrence and Distress.Journal of pain and symptom management · 2022Article
- HIV, psychological resilience, and substance misuse during the COVID-19 pandemic: A multi-cohort study.Drug and alcohol dependence · 2022Article
- Using 2D and 3D pluripotent stem cell models to study neurotropic viruses.Frontiers in virology (Lausanne, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of antiretroviral therapy (ART) has dramatically increased the lifespan of HIV patients but treatment is complicated by numerous adverse effects and toxicities. ART complications include neuropsychiatric, metabolic, gastrointestinal, cardiac, and numerous other toxicities, and clinicians often have to choose one toxicity over another to offer the best medication regimen for a patient. Some antiviral drugs cause significant neuropsychiatric complications, including depression, cognitive impairment, and sleep disturbance. Even in careful studies, it may be difficult to determine which effects are related to the virus, the immune system, or the treatment. Of the six currently marketed classes of antiviral drugs, the nucleoside reverse transcriptase inhibitors and the non-nucleoside reverse transcriptase inhibitors have been most commonly associated with neuropsychiatric complications. Within these classes, certain drugs are more likely to cause difficulty than others. We review the contention regarding the central nervous system (CNS) complications of efavirenz, as well as debate about the role of CNS penetration in drug effectiveness and toxicity. A thorough working knowledge of the neuropsychiatric consequences of ART allows clinicians to tailor treatment more successfully to individual patients as well as to identify ART more quickly as the source of a problem or symptom.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.